Sign in

CIK 0001497253

  • Non-accelerated filer
  • Smaller reporting company

VivoSim Labs, INC.

Sign in to watch
Ticker
VIVS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
Operating
EIN
271488943
Phone
+1 858-224-1000
Business address
11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121
Former names
ORGANOVO HOLDINGS, INC., REAL ESTATE RESTORATION & RENTAL, INC.
Open-market buys, last 90 days
$2,804
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$2,804. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Lialin Tony Serge +$3K Chief Commercial Officer 1 filing

Reading 60 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2016-08-17 Malloy Kirk Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-17 KESSEL MARK Director Grant or award +7,500 7,500
2016-08-17 KESSEL MARK Director Grant or award +7,500 15,000
2016-08-17 KESSEL MARK Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-17 KESSEL MARK Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-17 HOWSON TAMAR D Director Grant or award +7,500 7,500
2016-08-17 HOWSON TAMAR D Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-17 GLOVER JAMES T Director Grant or award +7,500 17,500
2016-08-17 GLOVER JAMES T Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-17 Baltera Robert Jr. Director Grant or award +7,500 146,006
2016-08-17 Baltera Robert Jr. Director Grant or award · Stock Option (Right to Buy) +18,500 18,500
2016-08-05 David Eric CSO & EVP Pre-Clinical Dev Sale −20,000 $4.55 $91K 706,306
2016-07-11 Presnell Sharon Collins Chief Scientific Officer Grant or award +50,000 119,064
2016-07-11 Presnell Sharon Collins Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +100,000 100,000
2016-07-11 Murphy Keith Chairman, CEO and President Grant or award +208,000 6,127,638
2016-07-11 Murphy Keith Chairman, CEO and President Grant or award · Stock Option (Right to Buy) +415,000 415,000
2016-07-11 Gallant Paul General Manager Grant or award +47,500 47,500
2016-07-11 Gallant Paul General Manager Grant or award · Stock Option (Right to Buy) +95,000 95,000
2016-07-11 David Eric CSO & EVP Pre-Clinical Dev Grant or award +50,000 726,306
2016-07-11 David Eric CSO & EVP Pre-Clinical Dev Grant or award · Stock Option (Right to Buy) +100,000 100,000

Page 11 of 13 · 259 trades